Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935961 · ClinicalTrials.gov registry record · Phase 1
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase 1 study of Head Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT00935961 is a Phase 1 study of Head Neck Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 39-participant average among 6 other Head Neck Cancer trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00935961, a Phase 1 study of Head Neck Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to test the safety of RAD001 (everolimus) tablets at different dose levels, when added to docetaxel and cisplatin. The investigators want to find out what effects, good and/or bad, that everolimus has when added to docetaxel and cisplatin as treatment for head and neck cancer.
Conditions Studied
Interventions
- DRUG RAD001 + docetaxel + cisplatin
Study Locations (5)
New York
- Memorial Sloan-Kettering Cancer Center at Commack - Commack
- Memorial Sloan-Kettering Cancer Center - New York
- Memorial Sloan-Kettering at Mercy Medical Center - Rockville Centre
- Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center - Sleepy Hollow
New Jersey
- Memorial Sloan-Kettering Cancer Center at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935961
The ClinicalTrials.gov registry entry for NCT00935961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 6 other Head Neck Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which RAD001 + docetaxel + cisplatin is the first listed.
NCT00935961 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00935961 about?
NCT00935961 is a clinical study titled "RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer". The purpose of this study is to test the safety of RAD001 (everolimus) tablets at different dose levels, when added to docetaxel and cisplatin. The investigators want to find out what effects, good and/or bad, that everolimus has when added to docetaxel and cisplatin as treatment for head and neck c...
What is the current status of trial NCT00935961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-07. Estimated completion is 2013-08.
What conditions does trial NCT00935961 study?
This clinical trial studies the following conditions: Head Neck Cancer.
What interventions are being tested in trial NCT00935961?
The interventions under investigation include: RAD001 + docetaxel + cisplatin (DRUG).
Who is sponsoring clinical trial NCT00935961?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00935961 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
RECRUITING · Phase 1
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
COMPLETED · Phase 1
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.